Baker Brothers portfolio, Q3 2025
Baker Bros. Advisors · 13F for the quarter ending Sep 30, 2025
For Q3 2025, Baker Bros. Advisors reported $13.8B across 91 US-listed positions, led by ONC (21.7%), INCY (18.8%) and MDGL (7.1%). Compared with its filing for Q2 2025, Baker Brothers opened 12 new positions, added to 14, reduced 5 and sold out of 10; 60 positions did not change.
The largest purchase was an addition to CELC ($121.8M); the largest sale, a reduction of INSM ($145.4M).
Key facts
- 13F portfolio value
- $13.8BQ3 2025
- Positions
- 91
- Largest holding
- ONC 21.7%
- New positions
- 12
- Sold out
- 10
- Filed
- Nov 14, 2025
Holdings as of (Q3 2025), filed with the SEC on . Changes are measured against the filing for Jun 30, 2025. Every tracked investor's Q3 2025 13F.
Bought and sold in Q3 2025
| Stock | Move | Shares | Size | Of portfolio |
|---|---|---|---|---|
| Insmed IncINSM | ▼ Reduced 13% | −1.01M | $145.4M | 1.05% |
| Celcuity IncCELC | ▲ Added 45% | +2.47M | $121.8M | 0.88% |
| Madrigal Pharmaceuticals IncMDGL | ▲ Added 8.4% | +165.68K | $76M | 0.55% |
| Abivax SAABVX | ▲ New | +875.8K | $74.4M | 0.54% |
| Alkermes PLCALKS | ▲ Added 26% | +1.68M | $50.4M | 0.36% |
Celcuity Incno ticker on file | ▲ New | — | $40.9M | 0.30% |
| Ionis Pharmaceuticals IncIONS | ▲ New | +566.8K | $37.1M | 0.27% |
| IDEAYA Biosciences IncIDYA | ▲ Added 55% | +1.16M | $31.5M | 0.23% |
| Rapport Therapeutics IncRAPP | ▲ Added 181% | +997K | $29.6M | 0.21% |
Avidity Biosciences Incno ticker on file | ▲ New | +625K | $27.2M | 0.20% |
| Structure Therapeutics IncGPCR | ▼ Reduced 38% | −952.66K | $26.7M | 0.19% |
| Arrowhead PharmaceuticalsARWR | ▲ Added 78% | +731.59K | $25.2M | 0.18% |
Verona Pharma Plcno ticker on file | ▼ Sold out | −223.84K | $21.2M | 0.15% |
Verve Therapeutics Incno ticker on file | ▼ Sold out | −1.69M | $19M | 0.14% |
| Immatics N.V.IMTX | ▲ Added 19% | +1.93M | $16.4M | 0.12% |
Blueprint Medicines Corpno ticker on file | ▼ Sold out | −125.54K | $16.1M | 0.12% |
| Viking Therapeutics IncVKTX | ▲ New | +366.08K | $9.6M | 0.07% |
| Pharvaris N VPHVS | ▲ New | +375K | $9.4M | 0.07% |
| Spyre Therapeutics IncSYRE | ▲ Added 60% | +373.3K | $6.3M | 0.05% |
| Heron Therapeutics IncHRTX | ▲ New | +4.25M | $5.4M | 0.04% |
| Xencor IncXNCR | ▲ Added 64% | +431.68K | $5.1M | 0.04% |
| MBX Biosciences IncMBX | ▲ New | +277.78K | $4.9M | 0.04% |
IGM Biosciences Incno ticker on file | ▼ Sold out | −4.1M | $4.6M | 0.03% |
| Cerus CorpCERS | ▼ Reduced 22% | −2.88M | $4.6M | 0.03% |
| Revolution Medicines IncRVMD | ▲ Added 1.0% | +90.39K | $4.2M | 0.03% |
Ventyx Biosciences Incno ticker on file | ▲ New | +1.02M | $3.2M | 0.02% |
| LB Pharmaceuticals IncLBRX | ▲ New | +200K | $3.2M | 0.02% |
| Fate Therapeutics IncFATE | ▼ Sold out | −2.49M | $2.8M | 0.02% |
| Contineum Therapeutics IncCTNM | ▼ Reduced 75% | −234.83K | $2.8M | 0.02% |
| CytomX Therapeutics IncCTMX | ▲ Added 22% | +766.6K | $2.4M | 0.02% |
| Candel Therapeutics IncCADL | ▼ Sold out | −355.11K | $1.8M | 0.01% |
| Rocket Pharmaceuticals IncRCKT | ▼ Sold out | −552.08K | $1.4M | 0.01% |
| Intellia Therapeutics IncNTLA | ▲ Added 2.7% | +71K | $1.2M | 0.01% |
| vTv Therapeutics IncVTVT | ▲ Added 52% | +51K | $1.2M | 0.01% |
Generation Bio Cono ticker on file | ▲ New | +194.49K | $1.2M | 0.01% |
HOOKIPA Pharma Incno ticker on file | ▼ Sold out | −812.81K | $1M | 0.01% |
| Neumora Therapeutics IncNMRA | ▼ Sold out | −1.03M | $758.7K | 0.01% |
Generation Bio Cono ticker on file | ▼ Sold out | −1.94M | $622.6K | 0.00% |
| KALA BIO IncKALA | ▼ Reduced 18% | −216.8K | $331.7K | 0.00% |
VYNE Therapeutics Incno ticker on file | ▲ New | +851.35K | $285.2K | 0.00% |
| Incyte CorpINCY | ▲ Added 0.00% | +388 | $32.9K | 0.00% |
Holdings at the quarter's end
| # | Stock | Sector | Share of portfolio | Value | Shares | Reported price | Held | Since Q2 2025 |
|---|---|---|---|---|---|---|---|---|
| 1 | Beone Medicines LtdONC · SPONSORED ADS | Health Care | 21.7% | $3B | 8.8M | $340.70 | 6+ qtrs | No change |
| 2 | Incyte CorpINCY | Health Care | 18.8% | $2.6B | 30.74M | $84.81 | 6+ qtrs | ▲ Added 0.00% |
| 3 | Madrigal Pharmaceuticals IncMDGL | Health Care | 7.10% | $982.3M | 2.14M | $458.66 | 6+ qtrs | ▲ Added 8.4% |
| 4 | Insmed IncINSM | Health Care | 6.98% | $965.4M | 6.7M | $144.01 | 6+ qtrs | ▼ Reduced 13% |
| 5 | Acadia Pharmaceuticals IncACAD | — | 6.62% | $915.4M | 42.9M | $21.34 | 6+ qtrs | No change |
| 6 | Summit Therapeutics IncSMMT | Health Care | 5.04% | $696.7M | 33.72M | $20.66 | 6+ qtrs | No change |
| 7 | Rhythm Pharmaceuticals IncRYTM | Health Care | 4.09% | $566M | 5.6M | $100.99 | 6+ qtrs | No change |
| 8 | Revolution Medicines IncRVMD | Health Care | 3.19% | $441.6M | 9.46M | $46.70 | 6+ qtrs | ▲ Added 1.0% |
| 9 | Celcuity IncCELC | — | 2.83% | $391M | 7.92M | $49.40 | 6+ qtrs | ▲ Added 45% |
| 10 | Kymera Therapeutics IncKYMR | Health Care | 2.72% | $376.5M | 6.65M | $56.60 | 6+ qtrs | No change |
| 11 | Kodiak Sciences IncKOD | Health Care | 2.05% | $283.4M | 17.31M | $16.37 | 6+ qtrs | No change |
| 12 | Alkermes PLCALKS · SHS | Health Care | 1.75% | $242.7M | 8.09M | $30.00 | 6+ qtrs | ▲ Added 26% |
| 13 | Abcellera Biologics IncABCL | — | 1.00% | $138.5M | 27.53M | $5.03 | 6+ qtrs | No change |
| 14 | Edgewise Therapeutics IncEWTX | Health Care | 0.86% | $118.5M | 7.31M | $16.22 | 6+ qtrs | No change |
| 15 | Kiniksa Pharmaceuticals InternationalKNSA · ORD SHS CL A | Health Care | 0.79% | $109.7M | 2.82M | $38.83 | 6+ qtrs | No change |
| 16 | Stoke Therapeutics IncSTOK | — | 0.79% | $108.9M | 4.63M | $23.50 | 6+ qtrs | No change |
| 17 | Immatics N.V.IMTX · SHS | — | 0.75% | $103M | 12.09M | $8.52 | 6+ qtrs | ▲ Added 19% |
| 18 | Grail IncGRAL | Health Care | 0.70% | $96.4M | 1.63M | $59.13 | 4 qtrs | No change |
| 19 | IDEAYA Biosciences IncIDYA | — | 0.64% | $89.1M | 3.28M | $27.21 | 6+ qtrs | ▲ Added 55% |
| 20 | Immunovant IncIMVT | Health Care | 0.64% | $88M | 5.46M | $16.12 | 6+ qtrs | No change |
| 21 | Immunocore Holdings plcIMCR · ADS | — | 0.61% | $84.4M | 2.32M | $36.33 | 6+ qtrs | No change |
| 22 | Bicycle Therapeutics PlcBCYC · SPONSORED ADS | — | 0.61% | $84.3M | 10.89M | $7.74 | 6+ qtrs | No change |
| 23 | Ultragenyx PharmaceuticalRARE | — | 0.60% | $83.4M | 2.77M | $30.08 | 6+ qtrs | No change |
| 24 | Abivax SAABVX · SPONSORED ADS | Health Care | 0.54% | $74.4M | 875.8K | $84.90 | 1 qtr | New |
| 25 | Arrowhead PharmaceuticalsARWR | Health Care | 0.42% | $57.6M | 1.67M | $34.49 | 2 qtrs | ▲ Added 78% |
| 26 | Roivant Sciences LtdROIV · SHS | Health Care | 0.41% | $57M | 3.77M | $15.13 | 6+ qtrs | No change |
| 27 | Denali Therapeutics IncDNLI | — | 0.39% | $54.2M | 3.73M | $14.52 | 6+ qtrs | No change |
| 28 | Merus N Vno ticker on file | — | 0.39% | $54.1M | 574.38K | $94.15 | 6+ qtrs | No change |
| 29 | Intellia Therapeutics IncNTLA | — | 0.34% | $47.4M | 2.75M | $17.27 | 4 qtrs | ▲ Added 2.7% |
| 30 | Replimune Group IncREPL | — | 0.33% | $46.3M | 11.05M | $4.19 | 6+ qtrs | No change |
| 31 | Rapport Therapeutics IncRAPP | — | 0.33% | $45.9M | 1.55M | $29.70 | 2 qtrs | ▲ Added 181% |
| 32 | Structure Therapeutics IncGPCR · SPONSORED ADS | — | 0.32% | $43.6M | 1.56M | $28.00 | 5 qtrs | ▼ Reduced 38% |
| 33 | Celcuity Incno ticker on file · NOTE 2.75% 8/1/2031 | — | 0.30% | $40.9M | — | — | 1 qtr | New |
| 34 | Viridian Therapeutics IncVRDN | — | 0.27% | $37.6M | 1.74M | $21.58 | 2 qtrs | No change |
| 35 | Ionis Pharmaceuticals IncIONS | Health Care | 0.27% | $37.1M | 566.8K | $65.42 | 1 qtr | New |
| 36 | Praxis Precision MedicinesPRAX | Health Care | 0.26% | $36.5M | 689.49K | $53.00 | 6+ qtrs | No change |
| 37 | Monte Rosa Therapeutics IncGLUE | — | 0.26% | $36.4M | 4.92M | $7.41 | 6+ qtrs | No change |
| 38 | BioNTech SEBNTX · SPONSORED ADS | Health Care | 0.26% | $36.4M | 368.92K | $98.62 | 4 qtrs | No change |
| 39 | Nurix Therapeutics IncNRIX | — | 0.26% | $35.9M | 3.88M | $9.24 | 6+ qtrs | No change |
| 40 | Dianthus Therapeutics IncDNTH | Health Care | 0.23% | $31.1M | 789.76K | $39.35 | 2 qtrs | No change |
| 41 | Entrada Therapeutics IncTRDA | — | 0.20% | $28.2M | 4.87M | $5.80 | 6+ qtrs | No change |
| 42 | argenx SEARGX · SPONSORED ADR | Health Care | 0.20% | $27.9M | 37.76K | $737.56 | 6+ qtrs | No change |
| 43 | Avidity Biosciences Incno ticker on file | — | 0.20% | $27.2M | 625K | $43.57 | 1 qtr | New |
| 44 | Vaxcyte IncPCVX | Health Care | 0.17% | $23.1M | 640.89K | $36.02 | 6+ qtrs | No change |
| 45 | Disc Medicine IncIRON | — | 0.16% | $22.3M | 337.05K | $66.08 | 4 qtrs | No change |
| 46 | Cidara Therapeutics Incno ticker on file | — | 0.16% | $21.8M | 227.27K | $95.76 | 2 qtrs | No change |
| 47 | Celldex Therapeutics IncCLDX | — | 0.12% | $17.2M | 665.37K | $25.87 | 6+ qtrs | No change |
| 48 | Neurogene IncNGNE | — | 0.12% | $17.2M | 991.69K | $17.33 | 6+ qtrs | No change |
| 49 | Sera Prognostics IncSERA · CLASS A COM | — | 0.12% | $16.8M | 5.5M | $3.06 | 6+ qtrs | No change |
| 50 | Spyre Therapeutics IncSYRE | Health Care | 0.12% | $16.8M | 1M | $16.76 | 2 qtrs | ▲ Added 60% |
| 51 | Cerus CorpCERS | — | 0.12% | $15.9M | 10.01M | $1.59 | 6+ qtrs | ▼ Reduced 22% |
| 52 | Akero Therapeutics Incno ticker on file | — | 0.11% | $15.4M | 324.63K | $47.48 | 6+ qtrs | No change |
| 53 | Xenon Pharmaceuticals IncXENE | — | 0.11% | $14.9M | 370.21K | $40.15 | 6+ qtrs | No change |
| 54 | Dbv Technologies S A SponsoredDBVT · SPONSORED ADS | — | 0.11% | $14.6M | 1.46M | $10.00 | 6+ qtrs | No change |
| 55 | Prelude Therapeutics IncPRLD | — | 0.11% | $14.6M | 10.12M | $1.44 | 6+ qtrs | No change |
| 56 | Arcellx Incno ticker on file | — | 0.10% | $13.7M | 166.83K | $82.10 | 2 qtrs | No change |
| 57 | CytomX Therapeutics IncCTMX | — | 0.10% | $13.6M | 4.25M | $3.19 | 2 qtrs | ▲ Added 22% |
| 58 | Taysha Gene Therapies IncTSHA | — | 0.10% | $13.1M | 4M | $3.27 | 6+ qtrs | No change |
| 59 | Xencor IncXNCR | — | 0.09% | $12.9M | 1.1M | $11.73 | 6+ qtrs | ▲ Added 64% |
| 60 | Design Therapeutics IncDSGN | — | 0.09% | $12.9M | 1.71M | $7.53 | 6+ qtrs | No change |
| 61 | Nuvalent Incno ticker on file | — | 0.09% | $12.4M | 143.94K | $86.48 | 2 qtrs | No change |
| 62 | Sionna Therapeutics IncSION | — | 0.09% | $11.8M | 400K | $29.41 | 3 qtrs | No change |
| 63 | Crinetics Pharmaceuticalsno ticker on file | — | 0.08% | $11.7M | 280K | $41.65 | 2 qtrs | No change |
| 64 | Viking Therapeutics IncVKTX | — | 0.07% | $9.6M | 366.08K | $26.28 | 1 qtr | New |
| 65 | Pharvaris N VPHVS | — | 0.07% | $9.4M | 375K | $24.95 | 1 qtr | New |
| 66 | Agios Pharmaceuticals IncAGIO | — | 0.06% | $7.6M | 189.87K | $40.14 | 2 qtrs | No change |
| 67 | Sana Biotechnology IncSANA | — | 0.05% | $7.2M | 2.03M | $3.55 | 6+ qtrs | No change |
| 68 | Sagimet Biosciences IncSGMT | — | 0.05% | $6.5M | 953K | $6.86 | 6+ qtrs | No change |
| 69 | Alumis IncALMS | — | 0.05% | $6.2M | 1.56M | $3.99 | 6+ qtrs | No change |
| 70 | Relay Therapeutics IncRLAY | — | 0.04% | $6.1M | 1.16M | $5.22 | 6+ qtrs | No change |
| 71 | Skye Bioscience IncSKYE | — | 0.04% | $5.7M | 1.45M | $3.93 | 6+ qtrs | No change |
| 72 | Heron Therapeutics IncHRTX | — | 0.04% | $5.4M | 4.25M | $1.26 | 1 qtr | New |
| 73 | TScan Therapeutics IncTCRX | — | 0.04% | $5.1M | 2.78M | $1.82 | 6+ qtrs | No change |
| 74 | MBX Biosciences IncMBX | — | 0.04% | $4.9M | 277.78K | $17.50 | 1 qtr | New |
| 75 | vTv Therapeutics IncVTVT · CL A | — | 0.03% | $3.5M | 148.31K | $23.35 | 6+ qtrs | ▲ Added 52% |
| 76 | Ventyx Biosciences Incno ticker on file | — | 0.02% | $3.2M | 1.02M | $3.11 | 1 qtr | New |
| 77 | LB Pharmaceuticals IncLBRX | — | 0.02% | $3.2M | 200K | $15.79 | 1 qtr | New |
| 78 | Vir Biotechnology IncVIR | — | 0.02% | $3.1M | 542.54K | $5.71 | 4 qtrs | No change |
| 79 | Wave Life Sciences LtdWVE · SHS | — | 0.02% | $2.5M | 344.06K | $7.32 | 5 qtrs | No change |
| 80 | Enliven Therapeutics IncELVN | — | 0.02% | $2.4M | 114.83K | $20.47 | 6+ qtrs | No change |
| 81 | Protara Therapeutics IncTARA | — | 0.02% | $2.3M | 536.83K | $4.35 | 6+ qtrs | No change |
| 82 | Tectonic Therapeutic IncTECX | — | 0.01% | $1.6M | 100K | $15.69 | 3 qtrs | No change |
| 83 | KALA BIO IncKALA | — | 0.01% | $1.5M | 985.09K | $1.53 | 6+ qtrs | ▼ Reduced 18% |
| 84 | Generation Bio Cono ticker on file | — | 0.01% | $1.2M | 194.49K | $6.12 | 1 qtr | New |
| 85 | Contineum Therapeutics IncCTNM · CL A | — | 0.01% | $912.6K | 77.67K | $11.75 | 6+ qtrs | ▼ Reduced 75% |
| 86 | Aligos Therapeutics IncALGS | — | 0.01% | $813.9K | 83.06K | $9.80 | 6+ qtrs | No change |
| 87 | VYNE Therapeutics Incno ticker on file | — | 0.00% | $285.2K | 851.35K | $0.3350 | 1 qtr | New |
| 88 | Tyra Biosciences IncTYRA | — | 0.00% | $148.4K | 10.61K | $13.99 | 6+ qtrs | No change |
| 89 | Acrivon Therapeutics IncACRV | — | 0.00% | $41.3K | 22.81K | $1.81 | 6+ qtrs | No change |
| 90 | Surrozen Incno ticker on file · W EXP 8/11/2026 | — | 0.00% | $14.8K | 833.33K | $0.0178 | 6+ qtrs | No change |
| 91 | Opthea Limitedno ticker on file · SPONSORED ADS | — | 0.00% | $0 | 2.09M | — | 6+ qtrs | No change |
By sector
| Sector | Share of portfolio | Value | Positions |
|---|---|---|---|
| Health Care | 79.3% | $11B | 24 |
| No sector on file | 20.7% | $2.9B | 67 |
Questions and answers
What did Baker Brothers own in Q3 2025?
Baker Bros. Advisors's 13F for Q3 2025 lists 91 positions worth $13.8B. The largest: ONC (21.7%), INCY (18.8%), MDGL (7.1%), INSM (7.0%), ACAD (6.6%).
What did Baker Brothers buy in Q3 2025?
The largest purchases, by the shares bought at the quarter-end price the filing implies: CELC (added, $121.8M), MDGL (added, $76M), ABVX (new, $74.4M), ALKS (added, $50.4M), Celcuity Inc (new, $40.9M), IONS (new, $37.1M).
What did Baker Brothers sell in Q3 2025?
The largest sales: INSM (reduced, $145.4M), GPCR (reduced, $26.7M), Verona Pharma Plc (sold out, $21.2M), Verve Therapeutics Inc (sold out, $19M), Blueprint Medicines Corp (sold out, $16.1M), IGM Biosciences Inc (sold out, $4.6M).
When was this filing made?
Baker Bros. Advisors filed its 13F for the quarter ending Sep 30, 2025 on Nov 14, 2025. A 13F is due within 45 days of the quarter's end, so the positions were already weeks old when it became public.
Learn
Cite this page
Funkfolio, “Baker Brothers portfolio, Q3 2025: Baker Bros. Advisors 13F holdings”, data as of 14 November 2025. https://funkfolio.com/gurus/baker-brothers/2025-q3
Underlying data: SEC EDGAR, Form 13F-HR of Baker Bros. Advisors (CIK 1263508) for the period ending Sep 30, 2025.
Source: SEC EDGAR, Form 13F-HR for Baker Bros. Advisors (CIK 1263508), period ending Sep 30, 2025, filed Nov 14, 2025. Changes compare share counts with the filing for Jun 30, 2025; a share split in between is allowed for where one is on record. “Reported price” is a position's reported value divided by its shares. The size of a buy or sell is the change in shares at that price; a position sold out is sized at its value in the previous filing, and “of portfolio” sets the size against the $13.8B reported for this quarter. “Held” counts consecutive quarterly filings up to this one, out of the 6 looked at from here back. Sectors are those of the ranked companies on this site as they stand today. Not a live portfolio and not advice.